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AbsTrACT
Introduction Programme to eliminate neglected tropical 
diseases (NTDs) have gained global recognition, and may 
allow for improvements to universal health coverage and 
poverty alleviation. It is hoped that elimination of human 
African trypanosomiasis (HAT) Trypanosoma brucei 
gambiense (Tbg) would assist in this goal, but the financial 
costs are still unknown. The objective of this analysis was 
to forecast the financial burden of direct costs of HAT Tbg 
to funders and society.
Methods In order to estimate the total costs to health 
services and individuals: (1) potential elimination 
programmes were defined; (2) the direct costs of 
programmes were calculated; (3) the per case out-of-
pocket payments (OOPs) by programme and financial risk 
protection indicators were estimated. The total estimated 
costs for control and elimination programme were reported 
up till 2020 in international dollars. The mean results for 
both direct programme costs and OOPs were calculated 
and reported along with 95% CIs.
results Across sub-Saharan Africa, HAT Tbg maintaining 
‘Control’ would lead to a decline in cases and cost 
US$630.6 million. In comparison, the cost of ‘Elimination’ 
programme ranged from US$410.9 million to US$1.2 billion. 
Maintaining ‘Control’ would continue to cause 
impoverishment and financial hardship to households; 
while all ‘Elimination’ programme would lead to significant 
reductions in poverty.
Conclusion Overall, the total costs of either control or 
elimination programme would be near US$1 billion in the 
next decade. However, only elimination programme will 
reduce the number of cases and improve financial risk 
protection for households who are impacted by HAT Tbg.
InTroduCTIon
Over the last two decades, global health 
expenditures per capita have more than 
doubled, and continue to increase annually.1 
In several countries a large proportion of the 
health expenditure is funded by patients’ 
out-of-pocket with severe consequences to 
the financial protection of the household. 
However, policy makers at all levels rarely take 
into account the potential consequences on 
a household’s economic conditions of health 
summary box
What is already known?
 ► Financing sustainable health systems will increase 
Universal Health Coverage, but there are unknown 
costs related to elimination of neglected tropical 
diseases (NTDs); in particular, human African try-
panosomiasis (HAT) Trypanosoma brucei gambiense 
(Tbg).
 ► The cost-effectiveness of strategies to eliminate 
HAT Tbg have proven to differ by foci, but how this 
translates into financial burden for funders and the 
communities at risk is still unknown.
What are the new findings?
 ► National programmes that combine varying cost-ef-
fective strategies and lead to elimination of HAT Tbg 
will cost millions of dollars in the coming decade, 
but will improve financial protection (alleviate pover-
ty) by reducing the occurrence of catastrophic health 
expenditures to households impacted by HAT Tbg.
 ► Several countries burdened with sleeping sickness 
may not be able to afford optimal elimination pro-
grammes based on gross national income levels.
What do the new findings imply?
 ► Decision makers interested in elimination should not 
only consider the costs associated with the national 
programmes but also the societal perspective when 
prioritising programmes for the elimination of NTDs.
 ► Health financing and funding support will need to 
be addressed if elimination goals and sustainable 
development goals to eliminate poverty are to be 
achieved.
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policies and interventions. In the last decade, neglected 
tropical diseases (NTDs) increasingly attracted the 
interest of global health investors and there is currently a 
global mandate to achieve disease elimination of several 
NTDs.2 In order to comprehensively define the economic 
implications for NTDs in particular for key stakeholders, 
an ‘Eradication’ or ‘elimination investment case’ (EIC) 
framework was developed.3 At present, this approach 
has been applied to onchocerciasis (‘river blindness’) and 
lymphatic filariasis (‘elephantiasis’), highlighting that 
investments in elimination or eradication of such diseases 
leads to economic, health and ethical benefits.4–11 Thus 
far, cost-effective elimination strategies for human African 
trypanosomiasis (HAT). Trypanosoma brucei gambiense (Tbg) 
have been identified,12 and the ethical considerations of 
each strategy have been formally assessed13; however, a 
summary of the direct costs required for national control 
and elimination programmes have yet to be ascertained.
HAT Tbg, also known as ‘sleeping sickness’ is caused by 
the presence of the Tbg parasite that is transmitted by the 
bite of a tsetse fly from human reservoirs.14 Symptoms of 
the disease in the early stages include fever, headaches, 
joint pain and itching15; however, second stage symptoms 
resemble more severe neurological elements as the para-
site eventually crosses the blood brain barrier. Affected 
individuals in the second stage may display behaviour 
similar to that of a patient with mental illness leading 
to societal rejection, disdain and isolation even after 
the disease has been treated and the patient recovers.16 
Although several sub-Saharan nations have tsetse inhab-
ited areas with the potential of harbouring Tbg, currently 
there are only 13 endemic countries that still reported 
having HAT cases in 2013 according to the WHO Global 
Health Observatory.17 Patients infected with the disease 
are traditionally required to undergo a chemotherapy 
regimen at treatment centres that are accessible but 
often far from the villages of those most affected.18 This 
requires that patients be away from their families and 
absent from occupational obligations post-treatment 
resulting in financial consequences.16
Recent technological developments in treatments, 
surveillance approaches and diagnostics, along with 
feasible vector control interventions19 have shown that 
there are new alternatives to treat, identify and prevent 
HAT Tbg that are cost-effective. Decision makers now 
need to calculate the annual and future budget implica-
tions to sustain elimination strategies, as well as consider 
the economic implications for the communities involved. 
This study aims to estimate the potential costs associated 
with these two perspectives. First, to forecast the financial 
impact that elimination programmes may need to sustain 
elimination targets; second, to alert decision makers of 
the implications for financial risk protection to house-
holds affected by HAT Tbg.
MeTHods
In order to estimate the direct costs and financial risk 
protection impacts, the current control and potential 
elimination programmes at a national level needed to be 
defined. Then for each programme it was necessary to 
estimate the associated direct costs, households’ out-of-
pocket payments (OOPs) and financial risk protection 
indicators. Our approach considers both the perspective 
of the national and global funders who are interested 
in the direct costs associated with HAT Tbg elimination 
(including health services and vector control), and a 
households’ perspective (ie, OOPs). The mean results 
for both direct programme costs and household expendi-
tures are calculated along with 95% CI to express the 
uncertainty surrounding the mean simulations. Costs are 
discounted at 3% and reported from 2013 and 2020 for a 
time horizon of 7 years.
defining control and potential elimination programmes
A priority setting exercise was undertaken in order to 
define optimal programmes according to cost-effective-
ness and probability of elimination based on a previously 
published economic evaluation for strategies including 
new technologies in the elimination of Tbg.12 The 
micro-strategies originated from potential approaches 
to elimination foreseen with technologies that became 
available in 2013 and onwards described in Steinmann et 
al.19 The strategies ranged from adding new ‘tiny targets’ 
(small insecticide-impregnated screens) for vector 
control in addition to the current ‘screen and treat’ 
programmes that are readily available, to including a new 
oral tablet (oxaboroles) treatment that may eliminate the 
need for prolonged in-hospital treatment. These were 
further combined in Sutherland et al12 and modelled 
as five mutually exclusive macro-strategies for elimina-
tion to determine cost-effective options per foci. These 
strategies for elimination were further combined into 
national control and elimination programmes, based 
on the following cost-effectiveness thresholds: US$200 
per disability adjusted life year (DALY) averted, US$700 
per DALY averted, and US$1500 per DALY averted. Each 
programme is briefly described within table 1, with addi-
tional details for the approach provided in appendix A1.
Forecasting the financial impact of national programmes
A ‘bottom-up approach’ was used to estimate the total 
sub-Saharan costs. A dynamical transmission model 
developed by Stone and Chitnis20 has been used previ-
ously to estimate long-term costs and effects for control 
and elimination programmes for HAT Tbg.12 In our anal-
ysis, we exported the mean annual cost per person per 
foci (from 500 simulations) for each programme related 
to: surveillance (including diagnostics), treatment and 
vector control. These per person estimates were then 
projected to estimate country related costs based at risk 
populations areas14 and finally aggregated for a cumula-
tive cost across the 13 endemic sub-Saharan countries.21
Cost functions related to the expenses incurred 
for surveillance, treatment, diagnostics and vector 
control programmes of Tbg, using the inputs listed in 
appendix A2, were developed and described previously 
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Table 1 Description of programmes for control and elimination
Programme
Cost-effectiveness 
threshold Detailed description
Control Reference In alignment with the EIC methodology3 we use the ‘control’ as the counterfactual 
scenario which equates to recommendations by the WHO during 2013: total reliance on 
passive reporting in low transmission areas, biennial screening in moderate areas and 
annual screening in high transmission with the screening and treatment of CATT and 
pentamidine (stage1)/NECT (stage 2), respectively
Elimination I ~US$200 per DALY 
averted’
Involves the recommended surveillance levels for HAT Tbg by ‘Control’, but switching 
to new technologies for treatment (fexinidazole and oxaboroles) and diagnostics (rapid 
diagnostics with motorbike screening campaigns) in all areas but not implementing 
vector control strategies including ‘tiny targets’ (small insecticide-impregnated 
screens38)
Elimination II ~US$700 per DALY 
averted
Involves biennial surveillance in low risk transmission areas, currently recommended 
surveillance levels for HAT Tbg by WHO in moderate and high risk areas, switching to 
new technologies for treatment and diagnostics in all areas, and implementing vector 
control strategies including ‘tiny targets’ but only in high risk transmission areas
Elimination III ~US$1500 per DALY 
averted
Involves biennial surveillance in low risk transmission areas, currently recommended 
surveillance levels for HAT Tbg by WHO in moderate and high risk areas, switching 
to new technologies for treatment and diagnostics in all areas, and implementing 
vector control strategies including ‘tiny targets’ but only in moderate and high risk 
transmission areas
*WHO surveillance recommendations: low risk (no active surveillance, passive surveillance only), moderate—biennial surveillance, high—
annual surveillance.
CATT, card agglutination trypanosomiasis test; DALY, disability adjusted life years; EIC, eradication investment case; HAT Tbg, human African 
trypanosomiasis Trypanosoma brucei gambiense; NECT, nifurtomix-eflornithine combination therapy.
in Sutherland et al.12 The dynamical transmission model 
was then run for various strategies by foci (eg, strategy 
A, strategy E, and so on) to generate an annual cost per 
person in an at risk transmission area.12 These per person 
estimates were taken directly from the model outputs 
and then multiplied to the at foci defined by WHO14 and 
calculated for current at risk populations of the endemic 
countries. The formula to represent these calculations 
can be described as follows in Equation 1:
Equation 1. Costs per foci
 
30∑
t=1
C¯f =
(
csur + ctx + cvc
)
f
× nf
 
where t represents the years and  ¯C are the mean costs 
over the 30 year time horizon. The costs for surveillance 
is Csur, treatment is Ctx and vector control is Cvc. All are 
represented as units per person in an at risk focus, hence 
n is the number of people at risk in a focus. A specific 
focus is represented by f for which there are three: low, 
moderate and high. Additional details for the strategy 
related costing are presented in Sutherland et al.12
Equation 2. Total costs per programme (including all 
foci)
 T¯C = C¯low + C¯moderate + C¯high 
Hence, any given national programme (eg, Control, 
Elimination I, and so on) is the total cost of the low, 
moderate and high areas (refer to Equation 2).
Forecasting financial protection (financial protection analysis)
The estimated number of cases based on the four afore-
mentioned programmes for control and elimination, 
were simulated across sub-Saharan Africa, again using 
the model published by Stone and Chitnis.20 These esti-
mations are further described in appendix A3.1. It was 
assumed that each estimated Tbg case would represent 
a single household. A financial risk protection anal-
ysis (FPA) model was built in MS Excel 2010, and used 
Bayesian sampling techniques to estimate the household 
related data required for the FPA including: income, 
non-medical (NM) expenses (ie, food) and medical (M) 
expenses (ie, OOPs). Consumption (C), in our case the 
median income, of US$1360 per annum was derived 
from the average gross national income (GNI) of the 13 
endemic nations impacted by Tbg, with costs of non-med-
ical expenses (ie, food) derived from the literature.22 23 
The total medical expenses paid by households was esti-
mated from HAT studies found in the literature as well.24 
A cost function per household OOP expenditure was 
then developed, taking into consideration that a family 
member or friend would attend the treatment clinic with 
the diagnosed individual, and was calculated as follows:
Equation 3. Out-of-pocket (OOP) household 
expenditures
 
30∑
t=1
¯OOPsi = pi ×
[
cfee +
(
caccomodation ×
(
txdayssi + rdayssi
))
+2
(
ctransportation
)
+ 2
(
cmeals ×
(
txdayssi + rdayssi
))
 
where pi are the number of cases per stage, and c costs 
refer to meals (cmeals), a return trip for transportation to 
the treatment facility (ctransportation) and the per diem accom-
modation rates (caccomodation). The per diem treatment days 
defined as  txdayssi  are relative the treatment in the foreseen 
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programme (ie, Control 2020, Elimination 2020, and so 
on), refer to appendix A3.2 for additional details.
Prices derived from the literature related to income 
and non-medical expenses, and OOPs related to HAT 
Tbg, were converted to international dollars (USD) using 
purchasing power parity listed in the World Economic 
Outlook database.25 Prices that were reported in Euros 
were converted to international dollars (USD) using the 
average exchange rates lists on the European Central 
Bank Statistical Data Warehouse. Once all costs were 
converted to USD, they were then inflated to 2013 dollars 
using average consumer price indices.26
The catastrophic health expenditures (CHEs) was 
calculated using the proportion of medical expenses 
related to HAT Tbg from a household’s total income, less 
a basic need (ie, food) as follows:
Equation 4. Catastrophic health expenditure (CHE)
 
M(
C−NM) 
The proportions of CHE at 10% and 25% were defined 
by the sustainable development goal (SDG) 3.8.2 (30). 
For the purpose of this analysis, we assumed that only 
36% of affected households would actually incur medical 
expenses.27 The rationale being that in many cases, house-
holds forgo payments that could potentially lead to cata-
strophic expenditures.27 We relax this assumption in the 
sensitivity analysis (SA). To visualise the impact that OOP 
had on a household relative to the poverty line (PL), a 
Pen Parades’ diagram, was generated. This image is often 
used to assist policy makers in reviewing the impact that 
OOP may have on subjecting households to poverty 
(impoverishing) or pushing families with an income 
below the PL, further into poverty (‘immiserising’). In 
addition, we also conducted a SA within the FPA to eval-
uate the impact on financial protection when there were: 
variations in the proportion of households that incur 
OOPs related to HAT Tbg, higher and lower definitions 
of the PL, and increases and decreases to the annual 
discount rate.
A normal distribution was applied to case estimates, 
while gamma distributions were applied to all cost inputs. 
A PL of US$1.9 per diem28 was used to account for the 
economic status of sub-Saharan Africa. It was assumed 
that the PL would be the same in 2013 and 2020. For each 
programme, 10 000 simulations were run to generate the 
mean reported outcomes and 95% CIs. To understand 
the potential impact of poverty with current and future 
technologies, the programme “Control 2013”14 was used 
as a comparative baseline measure to the alternative 
options. The outcomes of the FPA are reported across 
sub-Saharan African and by country income levels. Addi-
tional details for input parameters used in the FPA are 
provided in appendix A3.
Patient and public involvement statement
No patients or public participants were involved in this 
study.
resulTs
Financial impact
From 2013 until 2020, the cumulative costs of control 
and elimination programme of the strategies modelled 
are listed in table 2. The results demonstrate that main-
taining the current control programme, without taking 
new technologies into consideration, will incur a total 
cost of US$630.6 million across sub-Saharan Africa. Intro-
ducing the first option of elimination programme (‘Elim-
ination I’) leads to a total financial impact of US$410.9 
million; while scaling up to ‘Elimination II’ would yield a 
total of US$988.0 million. Implementing ‘Elimination III’ 
across all sub-Saharan nations would lead to a total cost of 
US$1248.1 million. The net impact of each programme 
in comparison to ‘Control’ demonstrates that ‘Elim-
ination I’ would actually lead to cost-savings, while net 
increases of US$357.4 million and US$617.5 million for 
‘Elimination II’ and ‘Elimination III’, respectively.
If one evaluates the proportion of programme costs 
by GNI country levels, 80%–87% of financial burden for 
HAT Tbg will allotted to low-income countries (LICs) 
(refer table 2). In particular, the Democratic Republic of 
the Congo (DRC), which has the second lowest income 
of all the endemic sub-Saharan countries, but the highest 
number of cases, would be responsible for 65%–72% 
depending on the programme selected. Further more, 
if the GNI of a country is used as a proxy to determine a 
cost-effectiveness threshold, all countries could scale up 
to ‘Elimination I’, while 77% could consider ‘Elimination 
II’. Less than half (46%) of the endemic countries would 
be able to consider ‘Elimination III’ as good value for 
money using GNI as a threshold.
For each programme, as depicted in figure 1, the 
majority of costs for control and elimination programmes 
are driven by screening and diagnostic costs that come 
from passive surveillance, and/or active screening 
campaigns (68%–90% of total costs). The ongoing costs 
for control also begin to plateau after several years; while, 
although the costs of elimination programmes are high 
in the earlier years, they decline to 3%–5% of the overall 
costs in later years. The additional cost of vector control 
to ‘Elimination II’ and ‘Elimination III’ programmes 
contribute to 9% and 29% of the total programme costs, 
respectively.
Financial risk protection
The total number of expect cases and impacts related 
to poverty for all programmes completed in the finan-
cial protection analysis (FPA) are summarised in table 3. 
Overall, in comparison to the baseline year 2013, main-
taining a similar ‘Control’ programme till 2020 will not 
have an impact on poverty indices. Although the number 
of cases were forecasted to decline, the OOP health 
expenditures related to attending treatment centres for 
HAT treatment will still lead to impoverishment (22%), 
immiserisation (31%) and CHEs at both 10% and 25% 
of HAT Tbg households. Scaling up to ‘Elimination’ 
programmes, that result in medications that can be taken 
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at home or within local villages, will reduce the risk of 
impoverishment in the future by at least 5% for all elimi-
nation programmes in comparison to control and reduce 
the number of households facing CHEs to less than 1% 
(a reduction of 63%–30% depending on the thresholds 
selected). In addition, ‘Elimination’ programme lead to 
the fewest number of forecasted cases in the future. This 
dual impact is on households with Tbg is shown in the 
series of Pen’s Parade diagrams illustrated in figure 2.
Additional FPAs were evaluated by country income 
levels (refer table 3). The results again demonstrate that 
the (LICs) would be the most vulnerable to OOPs with 
99.4% and 98.8% of the households experiencing CHEs 
at 10% and 25%, respectively if ‘Control’ is maintained. In 
addition, although at first glance it appears that there are 
fewer being impoverished, this is only due to the fact that 
the majority of the households in LICs will risk immiser-
isation (approximately 85%) for healthcare payments 
related to HAT, even with ‘Elimination’ programmes. 
Low-income countries and middle-income countries 
(LMICs) have smaller populations of households at risk 
of impoverishment (0.49%) and CHEs when ‘Control’ is 
in place, however; introducing ‘Elimination’ programme 
could also eliminate CHEs and reduce the proportion of 
those impoverished to less than 0.5%. There is not fore-
seen risk to poverty related to HAT Tbg expenditures in 
upper-middle income countries (UMICs).
The results from the univariate SA of the FPA across 
sub-Saharan Africa did not deviate from the base case anal-
ysis when changes in the discount rate were completed, 
or the PL was lowered to US$1.25. In additional, even 
when 60%–75% of households paid the OOPs related 
to HAT Tbg, the FPA results remained similar. However, 
if only 36% of households incur OOPs when a family 
member is diagnosed with HAT, the impoverishing and 
immiserising proportions would be similar across all 
programmes, with fewer people experiencing CHEs. 
Nonetheless, the ‘Elimination’ programmes would still 
be the only programmes that could fully alleviate house-
holds from experiencing CHEs. The results of the SA are 
available in appendix A3.
dIsCussIon
Across sub-Saharan Africa, HAT Tbg control and elimi-
nation programmes will require substantial funding and 
fiscal commitments over the coming years. A ‘Control’ 
programme will lead to fewer cases in the coming years, 
but it will lead to delays in reaching elimination targets 
and it will still cost millions of dollars to funders. In 
addition, a ‘Control’ programme will have no impact on 
reducing OOPs and poverty indices encouraged by the 
SDGs. Moving to ‘Elimination’ is an attractive option, 
but the ‘Elimination’ programmes that are most likely 
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to reduce cases and alleviate OOPs related to HAT Tbg 
(Elimination II and III), are relatively expensive for 
the countries that share the greatest burden of at risk 
communities. The majority of the incremental funding 
required will need to be allocated to in-country surveil-
lance and diagnostics annually. This alerts a cause for 
concern for stakeholders seeking elimination, as tradi-
tionally only the treatments for HAT Tbg have been 
donated with the majority of healthcare costs reliant 
on non-profit organizations (NGOs) and the fragile 
national health system. In addition, in order for these 
programmes to reach the at risk population, substantial 
logistical and technical capacity would be required29 30 
which is not fully reflected in the simulated costs of the 
programmes.
The results of this two-part analysis demonstrate that 
there is a need for the global health community to prepare 
substantial funds for elimination, not only for treatments 
and preventative measures (ie, vector control) but also to 
the health system itself. In addition, it has demonstrated 
that the strive to elimination programmes may alleviate 
the households’ risk of impoverishment and thus contrib-
uting to reach the millennial SDGs.
The results of the analysis on financial burden high-
light that ‘Elimination’ programmes are the most favour-
able in achieving global goals. However, decision makers 
will have to assess the fiscal space needed especially since 
availability of new HAT treatments has historically had 
delays in Pan-African uptake in the market. There may 
be a risk that LICs will opt for the less aggressive ‘Elim-
ination I’ programme that would be cheaper. However, 
this will lead to a slower decline in cases compared with 
other elimination options and it could jeopardise the 
long-term goal of eliminating HAT. In addition, although 
the costs for OOPs expenses and direct programme costs 
have been converted to international dollars for ease of 
comparison, the true heterogeneity of costs across sub-Sa-
haran still need to be captured which will require cost 
data collection at the national level at the very least.
In addition, HAT is not the only NTD ear-marked for 
elimination/eradication, and so it must be kept in mind 
that there is still competition for funds even though the 
costs of elimination are known.9 This may pose a chal-
lenge for HAT during prioritisation of funding for NTDs. 
For example, the onchocerciasis, eradication and elim-
ination programmes are cost-saving relative to control 
and the per person at risk cost for HAT remains a rela-
tively costly disease with programme ranging from US$3 
to US$10 per person annually compared with ranges 
of US$1.5–US$3.9 per treatment in the onchocerciasis 
programme.9
HAT Tbg is already known to be a disease that affects 
the poor, but the current results demonstrate that house-
holds who are already near the PL, may fall: closer to the 
PL, under the PL (impoverished), or further into poverty 
(immiserised). However, the results of this analysis are 
still conservative as, recent evidence shows that there are 
often additional expenses prior to the diagnosis of HAT 
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A. Control 2013
B. Elimination 2020
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Figure 2 The Pen’s Parade diagramdepicts each household and their respective incomes pre-consumption (prior toincurring 
non-medical (NM) medical expenses (M) related to HAT Tbg and post-consumption (householdincome after incurring non-
medical (NM) needs and medical (M) HAT Tbg expenses); HAT Tbg, human African trypanosomias Trypanosoma brucei 
gambiense; OOP, out-of-pocket payment; PL, poverty line; USD, US dollar.
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as households seek alternative care and guidance when 
family members are ill.31
Although the methodology for poverty assessments 
using household surveys has been established,28 32 the 
approach of modelling prospectively to understand 
its impact on future technologies is novel. The FPA 
presented here is also not based on household surveys 
and instead relies on secondary data and modelling 
to generate conclusions. However, it demonstrates 
the potential to provide useful information in a deci-
sion-making context for new technologies. In addition, 
the FPA does not address other societal costs, such as the 
loss of wages, which has been done within an eradication 
investment case for other neglected diseases.5 9 These 
costs have recently been estimated along with other NTDs 
for elimination by Lenk et al,33 and demonstrate that the 
contribution of productivity loss to HAT is substantial.33
There are also economic gains from elimination that 
could be considered in future EIC assessments. For 
instance, tsetse free areas may increase access to water 
areas without menace and even land use opportunities. 
Future research in prospective FPA could consider if and 
how additional income to at risk communities (ie, house-
holds) may result from elimination and assist to offset 
OOPs related to CHEs.
Although this analysis highlights the financial benefits 
of elimination programmes, at the time of its inception, 
it was assumed that novel interventions would arrive on 
the market as scheduled. The efficacy of fexinidazole 
has been proven34 and, while the European Medicines 
Agency (EMA)’s Committee for Medicinal Products for 
Human Use has adopted a positive scientific opinion 
in November 2018, the timeframe for its actual deploy-
ment is uncertain. In addition, previous modelling12 
estimated the arrival of a novel one time treatment in 
2018, while it is currently estimated to be submitted to 
the EMA in 2021.35 In the interim, subsidies for travel, 
accommodation and food could be considered, with the 
current national sleeping sickness control programmes 
(NSSCPs) to encourage patients to attend without the 
risk of incurring in financial hardship. Nonetheless, the 
scale up of elimination activities has begun in at least 
nine endemic nations,36 and there is a continual decline 
in cases supporting the model’s estimations.
Our results also assume 80% coverage is maintained 
for surveillance programmes. This coverage rate shows 
promise in leading to elimination but may be hard to 
achieve. Although 30% of the high transmission areas are 
covered, on average, only 2% of the continent is experi-
encing some level of screening. Furthermore, there are 
several countries that have not established formal NSSCPs 
(ie, Gambia, Guinea-Bissau, Liberia), although foci risk 
areas exist.37 Hence, the scale up to elimination will be 
substantial not only in funds, but for logistics on the 
ground. Scaling up coverage may reveal also that there 
are more cases than once thought, and adjustments to the 
elimination forecast and budgets will have to be made. 
Long-term commitments to funding postelimination will 
be needed as the possibility of asymptomatic cases and 
unknown reservoirs comes to the forefront. An example 
of this was seen recently in Ghana where one case was 
found in 2013 after 12 years of no cases being reported.
ConClusIon
Overall, the results demonstrate that an ‘Elimination II’ 
foci–specific programme that deploys: targets in high-
risk areas with annual surveillance, adopts new technol-
ogies in all areas and implements biannual surveillance 
in moderate and low transmission zones, remains within 
cost-effectiveness thresholds for some low and lower-
middle income countries. It could also achieve elimina-
tion goals for 2020 in the long-run and leads to finan-
cial protection for families impacted by HAT Tbg. Global 
stakeholders and funders should ensure that low-income 
countries whose NSSCPs are unable to secure funds 
nationally for elimination should be supported as they 
share a disproportionate load of the disease burden. The 
elimination of HAT Tbg does have a high cost, but with 
continued efforts and support from global stakeholders, 
it is hoped that those already at risk of poverty will not be 
the ones to pay for it.
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